Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GoodRx Holdings, Inc. - Class A Common Stock (NQ:GDRX)

2.750 +0.040 (+1.48%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GoodRx Holdings, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
News headline image
1 Cash-Producing Stock to Keep an Eye On and 2 We Avoid
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
News headline image
1 Value Stock to Target This Week and 2 Facing Headwinds
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued... 
Via StockStory
News headline image
3 Healthcare Stocks We Approach with Caution
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have... 
Via StockStory
Topics Stocks
News headline image
GoodRx to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From GoodRx Holdings, Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
GoodRx Stock Buzzes As TrumpRx Drug Pricing Shake-Up Draws BofA Warning On Core Business Model ↗
Via Stocktwits
News headline image
3 Stocks Under $10 That Fall Short
Investors can certainly boost their returns by concentrating on stocks trading between $1 and $10. However, a disciplined approach is necessary because many of these businesses are speculative and lack... 
Via StockStory
News headline image
Why GoodRx (GDRX) Stock Is Trading Lower Today
Shares of healthcare tech company GoodRx (NASDAQ:GDRX) fell 1.7% in the afternoon session after Barclays initiated coverage on the health-focused technology company with an "Underweight" rating and a... 
Via StockStory
Topics Government
News headline image
1 Profitable Stock Worth Your Attention and 2 We Turn Down
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. 
Via StockStory
News headline image
Natera, GoodRx, and Bio-Techne Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after reports revealed the Trump administration considered extending the Affordable Care Act (ACA) subsidies. 
Via StockStory
Topics Economy Government
News headline image
Clover Health, GoodRx, Moderna, UFP Technologies, and Masimo Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated... 
Via StockStory
Topics Economy
News headline image
3 Small-Cap Stocks That Fall Short
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
News headline image
Novo Nordisk Leans Into Affordability Amid Rising Competition ↗
Novo Nordisk offers limited-time $199 pricing on Wegovy and Ozempic, lowers self-pay costs, and prepares for a stronger Wegovy pill rollout. 
Via Benzinga
News headline image
GoodRx Launches New $39 Per Month Weight Loss Telemedicine Subscription, Unveils Industry-Leading Introductory Cash Price of $199 Per Month for Ozempic® and Wegovy®
From GoodRx
Via Business Wire
News headline image
5 Revealing Analyst Questions From GoodRx’s Q3 Earnings Call
GoodRx’s third quarter results were met with a moderate positive market response, as the company’s revenue modestly exceeded Wall Street expectations despite being flat year-over-year. Management... 
Via StockStory
Topics Earnings
News headline image
3 Value Stocks We Find Risky
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few... 
Via StockStory
News headline image
3 Low-Volatility Stocks with Open Questions
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
News headline image
GDRX Q3 Deep Dive: Manufacturer Solutions Growth Offsets Flat Prescription Volumes
Healthcare tech company GoodRx (NASDAQ:GDRX) reported revenue ahead of Wall Streets expectations in Q3 CY2025, but sales were flat year on year at $196 million. Its non-GAAP profit of $0.08 per share... 
Via StockStory
News headline image
GoodRx’s (NASDAQ:GDRX) Q3 Sales Top Estimates
Healthcare tech company GoodRx (NASDAQ:GDRX) reported Q3 CY2025 results exceeding the market’s revenue expectations, but sales were flat year on year at $196 million. Its non-GAAP profit of $0.08 per... 
Via StockStory
News headline image
GoodRx Reports Third Quarter 2025 Results
From GoodRx Holdings, Inc.
Via Business Wire
News headline image
GoodRx (GDRX) Q3 Earnings Report Preview: What To Look For
Healthcare tech company GoodRx (NASDAQ:GDRX) will be reporting earnings this Tuesday after market close. Here’s what to expect. 
Via StockStory
News headline image
Healthcare Technology Stocks Q2 Highlights: Tandem Diabetes (NASDAQ:TNDM)
Looking back on healthcare technology stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Tandem Diabetes (NASDAQ:TNDM) and its peers. 
Via StockStory
News headline image
Mark Cuban Isn't Convinced TrumpRx Is Going To 'Change The Game' But He's Giving Them 'Credit For Trying' ↗
Billionaire entrepreneur Mark Cuban offered rare praise for the Trump administration's push to lower prescription drug costs, calling its TrumpRx initiative "a good start," while still acknowledging... 
Via Benzinga
Topics Government
News headline image
GoodRx (GDRX): Buy, Sell, or Hold Post Q2 Earnings?
Over the past six months, GoodRx’s stock price fell to $3.94. Shareholders have lost 9.8% of their capital, which is disappointing considering the S&P 500 has climbed by 30.6%. This was partly due to... 
Via StockStory
Topics Stocks Supply Chain
News headline image
GoodRx Launches New Hair Loss Subscription for Men to Simplify Access to Affordable Treatment
From GoodRx
Via Business Wire
News headline image
3 Cash-Producing Stocks with Warning Signs
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
News headline image
Tandem Diabetes, agilon health, GoodRx, Neogen, and Fortrea Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. 
Via StockStory
Topics Economy Government World Trade
News headline image
Trump Administration Engages Pharmacies, GoodRx For TrumpRx Launch ↗
Pharmacies and GoodRx are in talks to join TrumpRx, a new drug pricing site aiming to lower prescription costs for U.S. consumers. 
Via Benzinga
Topics Government
News headline image
GoodRx Announces Date for Third Quarter 2025 Earnings Release and Conference Call
From GoodRx Holdings, Inc.
Via Business Wire
News headline image
Q2 Earnings Highlights: GoodRx (NASDAQ:GDRX) Vs The Rest Of The Healthcare Technology Stocks
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the healthcare technology industry, including GoodRx (NASDAQ:GDRX) and its peers. 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.